Keros Therapeutics, Inc. announced that it appointed Dr. Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. Dr. Seth was appointed as a Class II director with a term expiring at the Company?s 2025 annual meeting of stockholders. The Board also appointed Dr. Seth to serve as a member of the Compensation Committee of the Board.

Dr. Seth served as the President and Chief Executive Officer of Nura Bio Inc. for three years, until she retired in October 2022. From July 2017 to January 2019, Dr. Seth was the Chief Operating Officer of Vir Biotechnology, Inc. Prior to joining Vir, Dr. Seth was Senior Vice President and Global Head of the Biosimilars business for Biogen, Inc. since 2014. From 1998 through July 2017, Dr. Seth held a range of global leadership and general management roles at Biogen spanning drug development, commercialization and international operations, including founding Managing Director of Biogen Idec India and Program Executive for several of Biogen?s major cross-functional drug development programs and product launches.

Dr. Seth currently serves on the board of directors of Bio-Techne Corporation and Seagen Inc. Dr. Seth received a Ph.D. in biochemistry and molecular biology from University of Massachusetts Medical School and conducted her post-doctoral research at Harvard University in immunology and structural biology, both as a Howard Hughes Medical Institute Fellow. She is also a graduate of the Advanced Management Program at Harvard Business School. Following Dr. Seth?s appointment to the Board?s Compensation Committee, the membership of the three standing committees of the Board is as follows: Audit Committee: Mary Ann Gray (chair), Nima Farzan and Julius Knowles.

Compensation Committee: Carl Gordon (chair), Mary Ann Gray, Ran Nussbaum and Alpna Seth. Nominating and Corporate Governance Committee: Tomer Kariv (chair), Nima Farzan and Julius Knowles.